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Streptococcus equi Infections in Horses: Guidelines for Treatment,
Control, and Prevention of Strangles—Revised Consensus
Statement
A.G. Boyle , J.F. Timoney, J.R. Newton, M.T. Hines, A.S. Waller, and B.R. Buchanan
This consensus statement update reflects our current published knowledge and opinion about clinical signs, pathogenesis,
epidemiology, treatment, complications, and control of strangles. This updated statement emphasizes varying presentations in the
context of existing underlying immunity and carrier states of strangles in the transmission of disease. The statement redefines the “gold
standard” for detection of possible infection and reviews the new technologies available in polymerase chain reaction diagnosis and
serology and their use in outbreak control and prevention. We reiterate the importance of judicious use of antibiotics in horses with
strangles. This updated consensus statement reviews current vaccine technology and the importance of linking vaccination with
currently advocated disease control and prevention programs to facilitate the eradication of endemic infections while safely
maintaining herd immunity. Differentiation between immune responses to primary and repeated exposure of subclinically infected
animals and responses induced by vaccination is also addressed.
Key words: Equine infectious upper respiratory disease; Guttural pouch; Lymphadenopathy; Nasal discharge.
D isease caused by Streptococcus equi in horses, com-monly referred to as strangles, was reported by Jorda-
nus Ruffus in 1251. Although the official name of the
causative agent is S. equi subsp. equi, we have decided to
use the descriptive term S. equi throughout the consensus
statement based on its widespread usage in the scientific lit-
erature. Strangles is a costly, worldwide, highly infectious
upper respiratory disease of the equine. As of 2017, stran-
gles is a reportable disease in the United States and many
other countries.
Clinical Signs
Infection with S. equi is classically characterized by
abrupt pyrexia followed by pharyngitis and subsequent
abscess formation in the submandibular and retropharyngeal
lymph nodes. The disease can occur in horses of any age. In
a prospective voluntary surveillance of cases of acute upper
respiratory disease with testing of whole blood and nasal
swabs via quantitative polymerase chain reaction (qPCR) in
the United States, S. equi was the most common agent iden-
tified in horses of 6–10 years age.1 However, severity of dis-
ease varies greatly depending on the immune status of the
animal. Younger horses seem to exhibit more severe clinical
signs with lymph node abscess formation and rupture,
whereas older horses are often less severely affected and
recover more rapidly. While most horses display classic
clinical signs, not every horse presents the same way.
Pyrexia with lethargy become typically the first signs
occurring 3–14 days after exposure and before most horses
are contagious. The pyrexia is persistent and may exceed
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428C (107.68F) in some cases.2 Fever may persist until
lymph node abscesses rupture.
A significant pharyngitis frequently accompanies infection
with horses reluctant to eat or drink. Many will hold their
head in abnormal positions. Nasal discharge is not uncom-
mon with significant pharyngitis. Some horses will develop a
soft/mucoid cough, which may be associated with eating.
Squeezing the larynx will often cause marked pain, stridor, or
gagging followed by coughing. Endoscopy of the upper air-
way can identify pharyngeal lymphoid hyperplasia and pha-
ryngeal compression from enlarged lymph nodes. Similarly,
the nasal and ocular mucosa can become inflamed with puru-
lent ocular discharge from which S. equimay be isolated.
Lymphadenopathy is a typical clinical sign. Classically,
submandibular and retropharyngeal lymph nodes are involved,
although the parotid and cranial cervical lymph nodes are also
occasionally involved. Abscesses develop a thick fibrous cap-
sule and typically rupture between 7 days and 4 weeks after
infection. The initial evidence of a lymph node abscess is a
warm, diffuse swelling. As the abscess matures, serum may
ooze from the skin before rupture and drainage of a thick puru-
lent discharge. Depending on the location of the lymph node,
the abscess may rupture into the airway or guttural pouch pre-
senting as thick nasal discharge or may erupt externally,
through the skin as in the case of the submandibular or parotid
lymph nodes. Expulsion of large amounts of discharge from
the mouth or nose with coughing, eating, or a lowered head
position suggest empyema of the guttural pouch. Parotid and
retrobulbar abscesses can cause swelling around the eyelid
temporarily obstructing vision. Approximately 50% of horses
with guttural pouch empyema exhibit an intermittent unilateral
nasal discharge and cough.3
Inflammation associated with pharyngitis and lymph
node abscess formation/rupture may cause obstruction of
the upper respiratory tract (hence the name strangles) neces-
sitating a temporary tracheostomy. Neuropraxia may occur
resulting in temporary laryngeal hemiplegia, dysphagia, or
both. Damage to the recurrent laryngeal nerve and the sub-
sequent paralysis of the arytenoid cartilage may contribute
to the difficulty in breathing associated with upper airway
inflammation/swelling. Dysphagia may be noted, occasion-
ally with feed material or water refluxing from the nares.
Not all infections with S. equi are confined to the upper
respiratory tract with abscesses reported in multiple sites
including the brain, abdomen, and mammary gland, with
these cases commonly referred to as “bastard strangles.”
Lymphangitis of a limb has been observed (B.R. Buchanan,
unpublished observations). Additionally, cases of S. equi
pneumonia have been known to occur.
Pathogenesis
Upon entering the mouth or nose, S. equi attaches to cells
within the crypts of the lingual and palatine tonsils and to the
follicular-associated epithelium of the pharyngeal and tubal
tonsils.4 There is no evidence of colonization before penetra-
tion. Ligands responsible for binding may include exposed
surface proteins such as SzPSe. A few hours after infection,
the organism is difficult to detect on the mucosal surface, but
is visible within epithelial cells and subepithelial tonsillar
follicles. Thus, nasal or nasopharyngeal samples may be cul-
ture negative in the early stages of infection. Translocation
occurs in a few hours to the mandibular and retropharyngeal
lymph nodes that drain the pharyngeal and tonsillar region.
Complement-derived chemotactic factors generated after
interaction of complement with bacterial peptidoglycan
attract large numbers of polymorphonuclear neutrophils
although gross evidence of abscessation is not visible for 3–
5 days after S. equi enter the lymph node.5 Failure of neutro-
phils to phagocytose and kill the streptococci appears to be
due to a combination of the hyaluronic acid capsule, anti-
phagocytic SeM protein, H factor binding Se18.9, Mac pro-
tein, and other undetermined antiphagocytic factors released
by the organism.6 Final disposal of bacteria is dependent on
lysis of the abscess capsule and evacuation of its contents.
Nasal shedding of S. equi usually begins 2–3 days after
onset of fever and persists for 2–3 weeks in most animals.
Some animals that remain without clinical signs and have
preexisting immunity never exhibit detectable shedding. In
others, shedding may persist much longer should infection
persist in the guttural pouch or the sinus.7–9 Systemic and
mucosal immune responses are evident 2–3 weeks after
infection and coincide with mucosal clearance.10
The infectious dose of organisms propagated in media is
probably much higher than that required during natural
transmission because virulence factors essential for initial
attachment and penetration are more likely to be expressed
on in vivo propagated bacteria. (J.F. Timoney, unpublished
data). Inocula of less than 106 colony forming units are not
consistently effective in causing disease because lower
numbers of bacteria are likely to be efficiently removed by
mucociliary clearance. The larger the intranasal inoculum of
cultured S. equi, the shorter the incubation period, and the
more severe the disease.
If not treated with antibiotics, approximately 75% of
horses develop long-term convalescent immunity to stran-
gles as a result of individual immune response as well as
natural exposure to disease over time contributing to
reboosting and herd immunity.11–13 Horses in the immediate
convalescent phase are resistant to experimental challenge
with numbers of S. equi greatly exceeding those required to
produce the original infection.10 Approximately 20–25% of
convalescent horses become susceptible to a second attack
of the disease within several months, which probably repre-
sents a failure to produce or maintain an adequate concen-
tration of the relevant mucosal and systemic antibodies.10
Ongoing exposure to S. equi due to the presence of guttural
pouch carriers, possibly contributes to the maintenance of
increased levels of immunity and extended strangles-free
status within isolated herds of previously infected horses.
Older horses with residual immunity, foals with waning
maternal antibody protection, and vaccinated animals have
limited susceptibility and can develop a mild form of strangles
often termed “catarrhal or atypical strangles.” It is important
to realize that these animals shed virulent S. equi that will pro-
duce severe disease in more susceptible, often young, horses.14
Milk from mares that have recovered from strangles con-
tains immunoglobulin Gb (IgGb) and IgA with specificities
similar to those found in nasopharyngeal mucus of conva-
lescent horses.15 Suckling foals therefore benefit from the
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protective effects of these antibodies until weaned. Colostral
antibodies ingested during the first 24 hours of life recircu-
late to the nasopharyngeal mucosa, thus providing an addi-
tional source of protection to the foal during its first weeks.
Aspects of Pathogenesis Important in Control
and Prevention
 Shedding does not usually begin until a day or 2
after the onset of pyrexia making it possible to iso-
late new cases before they can transmit infection.
 Nasal shedding persists for 2–3 weeks in most ani-
mals. Horses may be infectious for at least 6
weeks after their purulent discharges have dried
up. Persistent guttural pouch infection may result
in intermittent shedding for years.
 Field and experimental data support the conclusion
that disease severity is correlated with the dose
and frequency of infectious challenge.
Epidemiology
Transmission
Active and recovering strangles cases are an important
and easily recognizable source of new S. equi infections for
susceptible horses through their purulent discharges from
lymph nodes, nose, and eyes. Transmission of S. equi infec-
tion occurs when there is either direct or indirect transfer of
these purulent discharges between affected and susceptible
horses. Direct transmission refers to horse to horse contacts,
which occurs through normal equine social behavior involv-
ing head-to-head and nose-to-nose contact. Indirect trans-
mission occurs with the sharing of contaminated housing,
water sources, feed or feeding utensils, twitches, tack, and
other less obvious fomites such as the clothing and equip-
ment of handlers and veterinarians and, anecdotally, even
via other animal species.16
It is now recognized that transmission originating from
outwardly healthy animals may be of greater importance
than that from purulent discharges from sick horses in ini-
tiating new outbreaks or recurrences in previously affected
herds because the source of infection is not obvious. Some
horses that are incubating the disease are outwardly healthy
and potentially infectious, but do, themselves, go on to
develop signs of strangles. It is assumed that nasal secre-
tions are the source of infection in these animals. Also of
importance are outwardly healthy convalescent cases that
continue to harbor the organism after full clinical recov-
ery.8,17 It is therefore appropriate to consider that all recov-
ered horses may be potentially infectious for at least 6
weeks after their purulent discharges have dried up. In a
proportion of outwardly healthy horses, carriage and at least
periodic shedding of S. equi occurs for prolonged periods
after apparent full and uncomplicated recovery. These
horses are commonly referred to as long-term, subclinical S.
equi carriers and there is strong evidence that they can be a
source of new or recurrent disease in well-managed groups
of horses.8,17 Effective strangles control measures require
detection, segregation, and treatment of carrier animals.18–20
Sequencing genomes of over 200 isolates of S. equi has
provided a global snapshot of its genetic diversity.21,22 Per-
sistence in the guttural pouch has been shown to drive both
the diversification and decay of its genome (S1).21,23
The Complex Epidemiology of Some Strangles
Outbreaks
In most cases, outbreak isolates are highly clonal, consist-
ent with an introduction and onward transmission from a
single source.21,23 However, in some cases, both active and
persistent carriage strangles strain were identified in chon-
droids removed from horses housed in the same stable dur-
ing a strangles outbreak. Evidence for the persistence of S.
equi leading to new clinical cases was observed after the
genomic analysis of isolates recovered from various large
outbreaks.21
Environmental Persistence of S. equi
S. equi remains viable in water for 4–6 weeks but not in
feces or soil. Despite older literature claiming extended sur-
vival in the laboratory setting,24 recent studies using real-
world scenarios showed rapid death (1–3 days) of the bacte-
ria on fencing and soil.25 S. equi is sensitive to bacteriocins
from environmental bacteria and does not readily survive in
the presence of other soil-borne flora.
Diagnosis
Bloodwork
Although bloodwork can be variable, a leukocytosis char-
acterized by a neutrophilia found on a complete blood count
as well as a hyperfibrinogenemia can be suggestive of infec-
tion with S. equi when examining an index case and should
encourage additional S. equi-specific testing.26,27
Sampling
Sensitivity and specificity of testing depends on the stage
of infection, the anatomical location from which the sample
is taken, the sampling technique, and the testing used.28–32
See Table 1 for sampling comparison. A needle aspirate
from an enlarged or abscessed lymph node is the optimal
sample for confirmation of S. equi infection; although mois-
tened nasopharyngeal swabs, as well as nasopharyngeal and
guttural pouch washes can also be used. As outlined previ-
ously under pathogenesis, S. equi rapidly invades the lymph
nodes of infected horses and is often not isolated from nasal
swabs or washes taken during the early stages of disease.
Therefore, a negative nasal culture or PCR test does not sig-
nify absence of S. equi infection—particularly if clinical
signs suggest otherwise.
Nasopharyngeal washes had increased sensitivity com-
pared to nasal swabs29 most likely because a greater surface
area within the internal nares is sampled, although these can
be problematical as animals can cough and sneeze during
sampling leading to loss of potentially contaminated sample
into the environment and onto the sampler. Use of rostral
nasal swabs may miss the intermittent shedding of S. equi
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from the guttural pouch into the nasopharynx and are rec-
ommended only if there is obvious mucopurulent nasal dis-
charge present that can be readily sampled. The use of
flocked swabs (with short fibers arranged perpendicular to
the swab shaft) has not improved the recovery of S. equi via
sampling29,32 or laboratory processing28,31 compared to the
more commonly used fiber wrapped swabs. Guttural pouch
sampling after recovery has been shown to increase the sen-
sitivity of detection of persistent S. equi infection compared
to repeated nasopharyngeal sampling, but has previously
been indicated for confirming subclinical carriage of S.
equi.31,32
Nasopharyngeal sampling involves slowly instilling about
50 mL of warm normal saline either via a 15 cm length of
soft latex tubing (5–6 mm diameter) or uterine pipette
inserted to the level of the nasal canthus and collecting the
washings into a disposable cup or rectal sleeve.33,34 These
washings are centrifuged, and the pellet was tested. Guttural
pouch sampling can be performed by introducing 50 mL of
warm saline visually via polyethylene tubing using the
instrument channel of an endoscope. Sampling blindly via a
stiff, bent catheter and recovering the washings can also be
performed, although these washings are not necessarily spe-
cific to the GPs as the sampling fluid negotiates the pharynx
and nasal passages before collection.
Testing
Culture
Specimens should be plated on Columbia CNA (colistin,
nalidixic acid) agar with 5% sheep or horse blood added.
The presence of other beta hemolytic streptococci, espe-
cially S. zooepidemicus, may complicate interpretation of
cultures. Zoocins produced by S. zooepidemicus will kill S.
equi and so strangles abscesses that rupture quickly can
become colonized and dominated by S. zooepidemicus. Col-
onies of commensal S. zooepidemicus are also typically
nonmucoid whereas fresh isolates from invasive infections
are sometimes mucoid. Unlike S. equi, S. zooepidemicus fer-
ments sorbitol and lactose. Culture provides a slow (results
take a minimum of 1–2 days to obtain) but low cost and
widely available method to detect S. equi, especially when
nasal discharges, fever, depression are first noticed in 1 or
more animals when they are likely to be actively shedding
large numbers of bacteria. Culture may, however, be unsuc-
cessful during the incubation, early clinical phases, and
when the bacterial count is low during convalescence.
Recovery can be as low as 40%.28,29,31 S. equi is normally
not present on the mucosa until 24–48 hours after the onset
of fever, and so horses monitored by daily measuring of rec-
tal temperatures during an outbreak may be recognized
early and isolated to limit transmission of S. equi. Studies
highlighting the reduced sensitivity of culture have resulted
in most, but not all authors (J.F. Timoney), concluding it is
no longer valid as the gold standard for the detection of S.
equi.2,28,29,31
Polymerase Chain Reaction
The PCR was originally designed to detect a partial DNA
sequence of SeM, the gene for the antiphagocytic M protein
of S. equi.35 A real-time PCR, otherwise known as quantita-
tive PCR and shortened to qPCR, has since evolved to
detect seeI, a superantigen-encoding gene.36 Currently, the
seeI qPCR is commercially available in the United States. A
variety of other sequences and qPCR formats have since
been documented in an effort to assure greater specificity
and sensitivity including, but not limited to eqbE and a tri-
plex qPCR (eqbE, SEQ2190, and an internal quality
Table 1. Comparison of S. equi samples.
S. equi Sample Pros Cons
Aspirate of mature abscessed lymph node High yield of bacterial organisms Requires this stage of disease
Moistened rostral nasal swaba Ease of sampling Animal needs to have active mucopurulent
discharge
Moistened nasopharyngeal swaba Ease of sampling False negatives possible in early febrile state
(not shedding yet)
False negatives possible due to intermittent
shedding from guttural pouch
Nasopharyngeal wash Ease of sampling False negatives possible in early febrile state
(not shedding yet)
Sampling more surface area False negatives possible due to intermittent
shedding from guttural pouch
Was found to be more sensitive than nasopha-
ryngeal swab29
Guttural Pouch lavageb Best for detection of carrier animals Special equipment needed
Experience entering the guttural pouch
More time consuming
False negative if lymph nodes have not yet rup-
tured into the pouch
aSynthetic microfiber flocked swabs have not shown increased detection rates over traditional rayon or cotton swabs.
bThe committee recommends guttural pouch lavage qPCR for the detection of carriers with concurrent visual inspection of the guttural pouch
via endoscopy. In order to limit the contamination of the environment and the veterinarians, we recommend collection directly from the guttural
pouch, rather than free catch from the nasal passage.
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control).30,36,37 Since the qPCR test can be completed
within 1–2 hours, results may be available on the same day
that samples arrive at the laboratory.
Quantitative PCR or other PCR formats used in North
America are approximately 3 times more sensitive than cul-
ture.18,35 PCR does not distinguish between dead and live
organisms, and so technically false-positive reactions poten-
tially undermine its absolute diagnostic value with respect
to detection of actual infection. However, positive experien-
ces of clinical application of qPCR in the diagnosis and con-
trol of field outbreaks of strangles in several countries and
management settings are testament to the usefulness of
qPCR over culture (A.G. Boyle/J.R. Newton/A.S. Waller,
unpublished observations). There has been clinical evidence
of transmission of strangles from horses with qPCR posi-
tive, culture negative guttural pouch lavage samples to na€ıve
animals.2 Even though, in theory, clinical samples which
contain polymerase inhibitors or abundant S. equi may give
negative PCR results when culture of the same sample con-
firms the presence of S. equi, review of clinicopathologic
data in the United Kingdom (J.R. Newton/ A.S. Waller,
unpublished data) demonstrates that this is an increasingly
rare phenomenon based on use of the triplex qPCR assay.30
For practicality, we recommend use of PCR testing of an
endoscopically guided guttural pouch lavage for detection
of S. equi in subclinically infected carrier animals. Visual
detection of inflammation of the guttural pouch respiratory
epithelium as well as the presence of empyema, chondroids,
or enlarged retropharyngeal lymph nodes on the floor of the
guttural pouch may suggest strangles even when the lavage
is negative for S. equi.
Serology
Different proprietary ELISAs are available for commer-
cial use targeting total IgG antibodies against different S.
equi surface proteins: SeM and the combined Antigen A (N-
terminal fragment of SEQ_2190 [Se75.3]) and Antigen C
(N-terminal fragment of SeM). The purpose of these tests
depends on which test is used and in which setting.
SeM Antibody Titer
Antibody titers to SeM minus its carboxy terminus (cur-
rently commercially available in the United Statesa,b and
Europec) peak about 5 weeks after exposure and remain high
for at least 6 months.13,15 Given the possibility that antibodies
directed against SzM of S. zooepidemicus could cross-react
with SeM, incubation of sera with heat-killed S. zooepidemicus
to remove cross-reactive antibodies was performed to enhance
test specificity.38 However, this process has not been adopted
in commercial assays. Considerable variation in the responses
of individual horses should be kept in mind when interpreting
results of measurement of anti-SeM antibody levels. Horses at
risk for development of purpura are hyper-responders and
make very strong antibody responses (1:3,200).39,40 The
SeM antibody titer can be used for the following purposes:
 Detection of recent infection evidenced by a 4-fold
or greater increase in titer of antibody in paired
sera taken 10 days apart.
 To support a diagnosis of existing S. equi-associ-
ated purpura hemorrhagica (titer 12,800)
 To support diagnosis of metastatic abscessation
(bastard strangles) (titer 12,800)
 To identify animals with existing high levels of anti-
body that might predispose to purpura hemorrhagica,
especially useful if within 1 year of disease or expo-
sure.37 Do not vaccinate if value is 1:3,200 (J.F.
Timoney, unpublished observations).39
Serologic values are not a measure of protection. The
SeM-specific titer cannot be used to determine carrier status
and a single value is not a measure of active infection. Titers
wane over time14,40 and horses that received antibiotic treat-
ment during an outbreak seem to mount a reduced immune
response and remain susceptible to reinfection.41
Combined Antigen A (SEQ_2190 N-Terminal
Fragment) and Antigen C (SeM N-Terminal Fragment)
An indirect ELISA (iELISA) assay using the N-terminal
portion of SeM, which is unique to S. equi (antigen C), has
been developed to overcome the problem of cross-reactivity
with S. zooepidemicus.42 The assay is performed alongside
a second iELISA to quantify the levels of antibodies against
the S. equi-specific portion of SEQ_2190 (antigen A, also
referred to as Se75.3) and a positive result is issued if either
or both of the iELISAs exceed the positive cut-off. This
resulted in similar sensitivity, but greater specificity when
compared to the whole SeM antibody titer.42 It is currently
available in Europe, Australia, and Dubai.d The combined
Antigen A and C iELISA can be used for the following pur-
poses provided currently available vaccines have not been
used in the population of horses:
 To identify recent infection as early as 2 weeks.
 To identify exposed animals without signs that
may still be harboring S. equi, (carriers) and which
may pose an otherwise unsuspected infectious risk
to other horses.
A blood sample taken from new arrivals can be used to
identify recently exposed or persistently infected horses. If
negative, a second blood sample taken 2 weeks later can
identify horses that have seroconverted and may have been
incubating the infection. If the second sample is also nega-
tive and the horse remains free from clinical disease, then it
is considered safe to enter the herd. Horses testing positive
via the blood test should be investigated further. Ideally, the
guttural pouches should be examined by endoscopy to iden-
tify signs of persistent infection and a saline wash should be
taken for analysis by qPCR. If qPCR tests on these samples
are negative then it is considered safe for the horse to enter
the herd. If any of the samples test qPCR positive or chon-
droids, empyema, or both are visible on endoscopy, then
debridement followed by topical treatment should be per-
formed. Combined Antigen A and C iELISA and qPCR can
be used to identify subclinically infected persistent carriers
at the end of an outbreak with it recommended that testing
commences no sooner than 3 weeks after resolution of signs
in the last clinical case, in order to allow animals that will
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clear short-term GP infections to do so without further
intervention.
Vaccination
Extract Vaccines
Currently a single purified M-protein antigen extract vac-
cine is available in the United States,e StrepvaxII, which
elicits serum antibody responses 7–10 days later.15 Na€ıve
horses require a schedule of 3 doses at an interval of 3
weeks. Booster doses are given once annually. An addi-
tional booster at 6 months of age is recommended for foals
when the initial series is started at less than 3 months of age.
Pregnant mares may be boosted a month before expected
date of foaling. Although potent with respect to SeM, effi-
cacy of extract vaccines in field studies has been disappoint-
ing. A reduction in clinical attack rate of only 50% was
reported in vaccinates a few weeks after the final booster.43
Adverse reactions include soreness or abscesses at injection
sites and occasional cases of purpura hemorrhagica.
Attenuated Live Vaccines
An attenuated live, intranasal vaccine,f Pinnacle IN, should
be administered only to healthy nonfebrile animals free of
nasal discharge. The vaccine is given in a schedule of 2 doses
at 2–3 week intervals. Annual booster doses are recom-
mended. The intranasal mode of application should be such
that an adequate amount of vaccine reaches the pharyngeal
and lingual tonsils. Safety issues include residual virulence
with formation of slowly developing mandibular abscesses in
a proportion of vaccinates,44–46 nasal discharge, and occa-
sional cases of immune-mediated vasculitis (purpura). Since
the vaccine contains live S. equi, accidental contamination of
remote injection sites or metastatic (hematogenous/lymphatic)
transfer from the pharynx will result in abscess formation at
these locations. For that reason, ideally no other vaccinations
are given concurrently and invasive procedures such as joint
injections, dental prophylaxis, and castrations should not be
performed during the same visit. No data are available on the
effect of concurrently administering a different intranasal vac-
cine. Vaccination with the modified live intranasal vaccine is
not recommended in foals less than 1 year of age due to risk
of significant clinical disease (fevers and lymph node enlarge-
ment) and increased shedding of the vaccine strain.44 A
genetic deletion has provided a reliable means of identifying
the vaccine from wild-type strains using colony characteristics
and PCR.46,47 The live vaccine should not be used during an
outbreak except in horses with no known contact with infected
or exposed animals. There are no published data to show that
vaccination in the face of exposure is detrimental, but there is
a risk of transmitting the virulent, wild S. equi to other horses
as they are vaccinated. Horses that have received intranasal
vaccine may test positive on PCR for up to 6 weeks.
Horses known to have had strangles within the previous
year or that have signs of strangles should not be vaccinated.
S. equi-specific serum antibody levels of horses within a
year of an outbreak should be assayed before decision to
vaccinate.40 Animals with titers of 1:3,200 or greater in the
SeM ELISA should not be vaccinated due to increased risk
of purpura hemorrhagica (J.F. Timoney, unpublished
observations).
A live attenuated aroA deletion mutant of S. equi vacci-
ne,g Equilis StrepE, is intermittently available in Europe for
administration submucosally on the inside of the upper lip.
Immunity to experimental challenge persists for about 3
months. The vaccine lacks DIVA (Differentiating Infected
from Vaccinated Animals) capability, which has been dem-
onstrated in serological monitoring of 1 outbreak after use
of this vaccine (J.R. Newton, unpublished data). Painful
reactions at injection sites may occur.48 Bacterial replication
of the vaccine strain has resulted in rare cases of clinical dis-
ease in vaccinated horses.49 Accidental veterinarian self-
injection has occurred.50
Efficacy of Multicomponent Vaccines
A multicomponent vaccine, Strangvac,h,51 in develop-
ment in Sweden has DIVA capability. Challenge studies
with a prototype of this vaccine52 were completed in Sep-
tember 2016 demonstrating a significant reduction in the
severity of disease 2 weeks and 2 months after the initial
series of 2 intramuscular injections and 2 weeks post-
booster vaccination given 3 months after the initial series of
2 intramuscular injections.52
Genomic S. equi Evaluations of Potential Relevance
to Vaccine Strain Selection
In genomic studies of S. equi strains, 3 major groups of
S. equi were described. Isolates from commercially available
live attenuated vaccines and the Se1866 isolate (the basis of
the multicomponent vaccineh), were included in the genomic
studies to determine the relationships of these vaccines to the
currently circulating population of S. equi. Interestingly, the
increasingly dominant strains in the United Kingdom grouped
together, but were genetically distant from the available live
attenuated vaccine strains.53 These data suggest that studies
are required to determine how well existing vaccines such as
Pinnacle, Strepvax, and Equilis StrepE confer cross-protection
against currently circulating strains.
Maternal Antibodies after Vaccination
Transfer of passive immunity to the foal mainly involves
antibodies of the IgGb isotype, which are distributed to the
serum and nasal secretions. Prepartum extract vaccination
of the mare significantly increases colostral levels of these
antibodies. Foals from vaccinated mares have significantly
higher titers of SeM-specific IgGb but not IgA in mucosal
washes during the first 2 months of life, although colostral
levels of SeM-specific IgA are significantly increased by
vaccination. Resistance of the foal to strangles during the
first months of life appears to be mediated by IgGb in muco-
sal secretions and milk and not by IgA. There are no data
available about colostral antibody levels after administration
of the intranasal or multicomponent vaccine administered to
broodmares.
There is no current consensus on the use of vaccines to
prevent S. equi. This is limited by geographical restrictions,
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varied experience, current lack of accepted proven efficacy,
and DIVA capabilities with the latest diagnostic assays.
Prevention
Quarantine and Screening
Limiting exposure still remains the best method to pre-
vent S. equi infections. Biosecurity measures should
include: quarantine and screening of all new arrivals, appro-
priate disinfection and cleaning of potentially contagious
equipment, and education of caretakers on proper hygiene.
Appropriate quarantine can be challenging on farms
where there is frequent movement of horses during breed-
ing, racing, or show seasons. New arrivals should be iso-
lated for at least 3 weeks. Additional screening for
subclinical carriers by guttural pouch endoscopy, culture,
and PCR testing should be part of any screening program. If
the animal is known to be unvaccinated and lives in a coun-
try where there is access to the combined SEQ_2190 and
SeM serology test, screening can be implemented as previ-
ously described under “Serology” section.42
Control of Outbreaks
At the beginning of a suspected outbreak, a detailed his-
tory should be collected from the horse owners, stable man-
agers, and caretakers. Questions pertaining to travel history,
management practices, and vaccine history are important.
The facility should be evaluated with the owner or manager
to discuss and develop a plan that is both logical and practi-
cal. The objectives should include identification and segre-
gation of infected horses to prevent further spread of
infection, including identifying any subclinical S. equi car-
riers and compliance with local laws regarding reporting
and movement restrictions. The general aims and measures
for such a strategy are outlined in Table 2.
Detection of Carriers with S. equi Infection of
the Guttural Pouches
Overall an average of 10% of horses in strangles out-
breaks experience apparent failure of the guttural pouch
drainage mechanism resulting in persistent GP empy-
ema.17,18 A recent retrospective of 108 strangles cases found
that 25 of 62 (40%) cases 40 days after initial diagnosis
were positive by culture or PCR assay of nasopharyngeal or
guttural pouch lavage samples. The median duration of pos-
itivity was 60 days (interquartile range 40–75 days).27 Gut-
tural pouch pathology associated with S. equi may persist
subclinically for many months or even years.8,9,17 In these
long-standing cases, pus in the pouches inspissates and then
eventually forms into discrete, ovoid, smooth concretions
known as chondroids that harbor viable S. equi on their sur-
face and within their core.8 Detection of guttural pouch
empyema with or without chondroids after strangles is best
achieved by direct visual assessment of both pouches using
endoscopy. Combined culture and PCR testing of lavage
samples collected via a sterile disposable catheter passed
through the biopsy channel of the endoscope are recom-
mended to accompany visual examination since infection
may be present in the absence of visible pathology. Diagno-
sis of guttural pouch empyema with or without chondroids
may also be made by radiography of the guttural pouch
area, although changes may not be visible in all cases. Iden-
tification, treatment, and elimination of guttural pouch S.
equi carriers has been proven to be effective in eradicating
infection in a herd.18,20 S. equi has been cultured from lav-
ages collected by direct percutaneous sampling of the pouch
although this is not recommended because of the high risk
of injury to important anatomical structures in the region.
Treatment of Carriers with S. equi Infection of
the Guttural Pouches
The method of treatment of guttural pouch empyema
depends on the consistency and volume of the material
within the pouches. Repeated lavages of pus-filled pouches
via rigid or indwelling catheters using isotonic saline or pol-
yionic fluid accompanied by subsequent lowering of the
head to allow drainage or use of a suction pump attached to
the endoscope, aid the removal of pus. Sedation aids in
implementation of endoscopy and facilitates drainage of
flush material from the guttural pouches by lowering the
horse’s head.
Both topical and prolonged systemic benzylpenicillin
administration (10 days) appear to improve treatment suc-
cess rate. Verheyen et al20 reported on the method of deliv-
ering a gelatin/penicillin mix. A solution of 50 mL gelatin/
penicillin is made as follows:
 Weigh out 2 g of gelatin (Sigma G-6650 or house-
hold grade) and add 40 mL sterile water.
 Heat or microwave to dissolve the gelatin.
 Cool gelatin to 45–508C.
 Meanwhile add 10 mL sterile water to 10,000,000
units (10 Mega) sodium benzylpenicillin G.
 Mix penicillin solution with the cooled gelatin to
make a total volume of 50 mL.
 Dispense into syringes and leave overnight at 48C
to set.
The gelatin–penicillin mix is retained in the pouches lon-
ger than a straight aqueous solution and is a useful way of
delivering a large dose of penicillin where it is needed.
Installation is easiest through a catheter inserted up the nose
and endoscopically guided into the pouch opening or
through polyethylene tubing via the endoscope. The catheter
works best with the last 2.5 cm bent at an angle to aid entry
under pouch flap. Recommendations include elevating the
horse’s head after infusion. Repeat infusions may be
required for more refractory cases.
Topical installation of 20% (w/v) acetylcysteine solution
has also been used to aid the treatment of empyema. Acetyl-
cysteine has a denaturing and solubilizing activity by dis-
rupting disulfide bonds in mucoprotein molecules, thus
reducing mucus viscosity and so theoretically facilitating
natural drainage. Erythema of the mucus membranes lining
the guttural pouch has been observed after installation of
20% (w/v) acetylcysteine solution. More long-standing
cases in which there is inspissation of the purulent material
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that does not readily drain into the pharynx are more diffi-
cult to treat topically as they can be refractory to large vol-
ume irrigation. Use of a memory-helical polyp retrieval
basket through the biopsy channel of the endoscope does
allow non-surgical removal of chondroids, even when
present in very large numbers and in conjunction with
empyema. When combined with topical and systemic anti-
microbial treatment, this is usually sufficient for cure of
severe guttural pouch lesions. Surgical hyovertebrotomy
and ventral drainage through Viborg’s triangle carries inher-
ent risks of general anesthesia and surgical dissection
around major blood vessels and nerves and S. equi contami-
nation of the hospital environment. This procedure has been
described standing, enabling it to be performed in the isola-
tion setting.54 Scarring of the pharyngeal openings of the
guttural pouch may preclude both natural drainage of puru-
lent material and endoscopic access to the guttural pouches.
Such cases may require conventional surgical or
Table 2. Aims and associated measures used to aid in control and transmission of S. equi.
Aim Measure
1. To prevent the spread of S. equi infection
to horsesa
 Quarantine new arrivals for 3 weeks. Additional screening for subclinical carriers by gut-
tural pouch endoscopy, culture, and PCR testing should be part of any screening program.
If animal is known to be unvaccinated and is located in a country that has access to the
combined SeM and SEQ_2190 serology, then seropositives should be identified and investi-
gated further via endoscopy (See “Serology” section).
 Stop all movement of horses on and off the affected premises immediately. Quarantine
should last for a minimum of 3 weeks past the resolution of the last clinical case and all
cases declared S. equi negative. Animals may be infectious for 6 weeks after discharges
clear. Persistent guttural pouch infection may result in intermittent shedding for years.
2. To prevent indirect cross infection by S.
equi from horses in the “dirty” area to
those in the “clean” area of the premises
 If S. equi infection is suspected, the horse should be isolated immediately to minimize the
risk of transmission to in contact animals.
3. Cohorting  Create 3 color-coded groups, even if limited space dictates that horses must remain in the
same paddock only separated by 2 layers of electric fence to avoid nose to nose contact.
The red group should include horses that have shown 1 or more clinical signs consistent
with strangles. Horses in the amber group are those that have had direct or indirect contact
with an infected horse in the red group and may be incubating the infection. The remaining
horses, in the green group, are those which have had no known direct or indirect contact
with affected animals.
 The rectal temperature of all horses in the green and amber groups should be measured
twice daily and any febrile horse should be moved to the red group.
 Clearly color-coded buckets and other equipment should be used to ensure that indirect
mixing between groups does not occur. Eliminate all sharing of water and disinfect water
and feed buckets daily.
 Wherever possible, dedicated staff should be used for each color-coded group. If separate
staff are not an option, staff should always move from the lowest risk to highest risk
groups, that is, from green to amber to red groups in that order and not back again.
4. To establish whether convalescing horses
are infectious after clinical recovery.
 Testing for potential carrier status should begin no sooner than 3 weeks after resolution of
clinical signs or potential exposure with no clinical signs.
 Testing horses that have been treated with antibiotics should not commence before 3 weeks
after the cessation of antibiotic treatment.
 If nasal discharge persists longer than 2 weeks, guttural pouch examination is indicated to
identify horses that may have empyema and require additional treatment.
 1 endoscopically guided guttural pouch lavage qPCR on cases and their contacts to screen for
carriers provides increased efficiency and sensitivity over 3 nasopharyngeal washes over 3
weeks. All equipment must be disinfected between horses when sampling multiples on a farm.
 Continual positive tests despite endoscopically normal guttural pouches should be consid-
ered infections and thought given to treatment with systemic antibiotics and sinus radiogra-
phy. Sites such as the sinuses should be considered in horses that continue to harbor S.
equi in the absence of pathology. Purulent discharge at the nasomaxillary opening should
be sampled if noted on endoscopy. Sinoscopy and qPCR testing of sinus lavage is possible,
but obviously invasive.
 If the outbreak is located in a country that has access to the combined SeM and SEQ_2190
serology, then seropositives identified in the in-contact population can be further investi-
gated via endoscopy (See “Serology” section).
 Animals are considered safe to move out of isolation on the basis of absence of obvious
guttural pouch pathology in conjunction with negative guttural pouch lavage qPCR results.
aThere is no current consensus on the use of vaccines to prevent S. equi. This is limited by geographical restrictions, varied experience, current lack
of accepted proven efficacy, and DIVA (Differentiating Infected from Vaccinated Animals) capabilities with the latest diagnostic assays (See
Vaccination).
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endoscopically guided laser treatments to break down scar
tissue and allow access to the pouches.
Biosecurity
Particular care should be taken with biosecurity measures
during strangles outbreaks to prevent indirect transfer of S.
equi from infectious horses (including potential subclinical
carriers) to susceptible animals (see Table 2). Dedicated
personnel and equipment must be available. Manure and
waste feed from infectious animals should be composted in
an isolated location.
It is important to adequately disinfect all potentially con-
taminated facilities and equipment. Surfaces should be
cleaned with a foaming soap agent to remove organic mate-
rial, rinsed and then thoroughly soaked in an appropriate liq-
uid disinfectant used according to the manufacturer’s
guidelines and allowed to dry. Use of high pressure systems
create risk of aerosolization of bacteria.55 Wooden surfaces
need adequate drying time before treatment with paint or
creosote. Replacement with new or alternative material may
be most appropriate. Although there is no evidence for pro-
longed survival of S. equi on pastures, those used to hold
infectious animals should be rested for several weeks after
animals are removed to allow denaturation of S. equi
through the effects of drying and direct sunlight, which are
best achieved during hot dry periods of prevailing weather.
Exposure to direct sunlight has been shown to be beneficial,
as cultured S. equi was shown to survive less than 24 hours
on wood, rubber, and metal surfaces when in direct sun-
light.25 Horse vans should be cleaned and disinfected after
each use. Stalls should be held open after cleaning/disinfec-
tion to allow for adequate contact time with disinfectant and
ideally through thorough drying of the surfaces.
Streptococcus spp., including S. equi, are relatively sus-
ceptible to disinfection. Some products commonly used
include hypochlorites (primarily household bleach), quater-
nary ammonium compounds,i phenolic compounds,j potas-
sium peroxymonosulfate,k and accelerated hydrogen
peroxides.l Chlorine compounds and quaternary ammo-
niums are not active in the presence of organic material,
therefore it is particularly important to thoroughly clean the
surfaces first. Diluted bleach and foot baths contaminated
by organic debris quickly become inactivated.56
Zoonotic Risks
Cases of S. equi infection in debilitated humans have
been reported, but are rare since S. equi is highly host
adapted.57–60 Animal handlers, care takers, veterinary prac-
titioners, pathologists, and equine post mortem attendants
should take particular care to avoid unnecessary contamina-
tion from infectious horses, especially avoiding respiratory
and oral contamination by purulent material.
Treatment
Appropriate treatment of horses with strangles usually
depends on the stage and severity of the disease. The major-
ity of strangles cases require no treatment other than proper
rest and a dry, warm stall and provision of soft, moist, and
palatable food of good quality while letting the disease run
its course. Food and water should be easily accessible to the
horse. In conditions of high summer temperature acute feb-
rile cases in stalls should have fan assisted ventilation.
Veterinary opinion as to whether or not to use antibiotic
treatment remains markedly divided.61 Clinical and experi-
mental evidence evaluating the effects of antibiotic use in
strangles is limited, and there are no reported prospective
studies comparing horses treated with antimicrobials to
untreated horses. In many cases, antibiotics are unnecessary,
and several potential concerns regarding their use have been
put forward. Some of these concerns include a delay in mat-
uration of abscesses or a recurrence of abscesses when anti-
biotics are discontinued. Conclusive data regarding the role
of antibiotics on increasing the risk of occurrence of meta-
static abscesses (“bastard strangles”) is lacking. In addition,
antibiotic treatment could potentially inhibit the synthesis of
protective antigens and affect the bacterial cell wall, which
in turn could diminish the development of protective immu-
nity.41A suboptimal immune response could leave horses
susceptible to reinfection.
Antibiotics may be indicated in some cases, although
these are always at the discretion of the attending veterinar-
ian including
 acutely infected animals with very high fever and
malaise before abscess formation,
 horses with profound lymphadenopathy and respi-
ratory distress,
 horses with metastatic abscessation,
 cases of purpura hemorrhagica treated with
corticosteroids,
 guttural pouch infections treated locally and sys-
temically to eliminate the carrier state.
 Antibiotics should NOT be used as a preventative in
animals that may have been exposed. Overuse of anti-
biotics, promotes resistance, provides a false sense of
security, and convalescent immune responses may not
be induced.
Horses with Early Clinical Signs
During an outbreak, immediate antibiotic therapy of new
cases in the early acute phase of infection with fever and leth-
argy may be curative and may prevent focal abscessation.
Usually, the time and dose of natural infection is not known,
thus making it difficult to determine the duration of treatment
needed for these animals. Premature cessation of antibiotics
can therefore result in prolonged disease rather than shorten-
ing. Good infection control and biosecurity is essential to pre-
vent re-exposure after discontinuation of treatment.
Horses with Lymph Node Abscessation
Once external lymphadenopathy is detected, antibiotic
therapy is generally ineffective. These cases primarily
require good nursing care. Specific therapy should be
directed toward enhancing maturation and drainage of the
abscesses. Topical treatments such as icthamol or a hot pack
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may be applied to promote maturation of the lymph node
abscess. Surgical drainage of lymph node abscesses may be
indicated if the abscesses do not rupture spontaneously;
however, it is critical to wait until the abscess has matured
and thinned out ventrally. Earlier surgical intervention may
only result in minimal exudate drainage and continued
lymph node swelling, because the abscess has enough inter-
nal structure (honeycomb loculations) to block drainage
through a single surgical incision. Daily flushing of the
open abscess with a 3–5% povidone iodine solution should
be continued until the discharge ceases.
The use of non-steroidal anti-inflammatory medications
such as phenylbutazone or flunixin meglumine may
improve the horse’s demeanor by reducing fever, pain, and
inflammatory swelling at the site of the abscesses. This may
in turn encourage eating and drinking. Consideration must
be given to the complications seen after the use of non-
steroidal anti-inflammatory medications in dehydrated and
anorectic horses. Rarely, affected horses may require inten-
sive supportive therapy, including intravenous fluids, feed-
ing by nasogastric tube, and tracheostomy.
Antibiotic therapy is indicated to decrease abscess size
and prevent complete airway obstruction in cases with signs
of respiratory distress including stridor. An animal requiring
a tracheostomy should be given systemic antimicrobial
drugs to prevent secondary bacterial infections of the lower
respiratory tract. Ideally, the duration of any treatment
should be guided with biweekly or weekly serial measure-
ments of inflammatory proteins, such as fibrinogen, to
ensure long enough treatment has been implemented.
Drugs of Choice for Treatment
Penicillin [22,000–44,000 iu/kg bwt IM q12h or IV q6h]
is generally considered the drug of choice for the treatment
of non-pneumococcal streptococcal disease, with the selec-
tion of alternative drugs depending on susceptibility, ease of
administration or the site of infection. S. equi is consistently
susceptible to penicillin. Laboratories (J.F. Timoney and
J.R. Newton, personal communications) handling hundreds
of S. equi strains have noted no emerging antibiotic resist-
ance to penicillin by S. equi or S. zooepidemicus. In general,
the incidence of resistance to most other drugs is low in S.
equi with the exception of aminoglycoside resistance,
including gentamicin, which is consistently observed.62
Recently, an increase in the percentage of all streptococcal
species resistant to enrofloxacin has been reported.63
The use of alternatives to penicillin therapy is often driven
by concerns about ease of administration, especially in those
horses that may require long-term treatment. Susceptibility
testing may help in antibiotic selection. Common alterna-
tives to penicillin include cephalosporins and macrolides
when age appropriate. Extra-label usage of ceftiofur has
been advocated for the treatment of S. equi when antibiotics
are indicated. Isolates of both S. zooepidemicus and S. equi
have been shown to be susceptible to ceftiofur in vitro and
the sustained release ceftiofur suspension has been shown to
be effective in the treatment of lower respiratory tract infec-
tion associated with S. equi subspecies zooepidemicus.64–66
Other than one anecdotal report of long acting ceftiofur
[6.6 mg/kg IM q96h] use during a large strangles outbreak
improving treatment compliance and resulting in final reso-
lution, there are no data on its efficacy in vivo.67 In order to
honor antibiotic use stewardship, cephalosporins should be
reserved for those animals in which compliance is difficult.
Anecdotal reports of the efficacy of trimethoprim-
sulfadiazine (TMS) [30 mg/kg PO q12h] in the treatment of
strangles are variable. Based on in vitro antimicrobial sus-
ceptibility testing where testing methods follow the Clinical
and Laboratory Standards Institute’s guidelines, the major-
ity of S. equi isolates are susceptible to TMS.68,69 However,
this may not translate into in vivo efficacy. While there is
evidence that TMS did not eliminate S. zooepidemicus
infection in tissue chambers implanted SC in ponies, the
study did not determine its effectiveness against S. equi.70
TMS has been seen to fail repeatedly in the treatment of
strangles (A.G. Boyle, unpublished observations).
Complications Associated with S. equi Infection
The overall complication rate increases with duration and
intensity of exposure and may be as high as 20%.71,72 Isola-
tion of infectious horses is therefore critical in reducing the
complication and case fatality rates. In a study in which data
were collected from a farm with 235 horses; 74 horses had
strangles, 15 of which (20.3%) had complications.71
Overall case fatality rates can be as high as 8.1%69 to
9.7%67 on large farm outbreaks. A more recent field study
comparing 108 strangles cases from smaller farms (<50
horses) to 215 cases with fevers of other origin over a 7-
year period found a much lower strangles case fatality rate
of 0.9% compared to the controls (3.2%).27
A variety of complications can occur as a result of stran-
gles. These can be generally grouped as:
 Those associated with the spread of infection from
the head and neck region to other locations exclud-
ing the guttural pouches (an inevitable percentage
of animals in which retropharyngeal lymph node
abscessation will burst into the guttural pouch as
the weakest line of resistance).
 Immune-mediated processes, including purpura
hemorrhagica and myopathies
Another rare complication of strangles is extension of
infection to the sinuses.7,8,20 Horses with infection in the
sinuses may become carriers. Other reported sequelae asso-
ciated with S. equi infection include anemia,26 agalactia,
myocarditis, endocarditis, panophthalmitis, periorbital
abscesses, ulcerative keratitis, paravertebral abscesses, men-
ingitis, funiculitis, septic arthritis, and tenosynovitis.26,73–77
Complications Associated with Metastatic Spread of
Infection
S. equi may potentially infect any anatomic site. The term
bastard strangles is often used to describe metastatic absces-
sation. Spread of the organism may occur through several
routes, including hematogenous spread, lymphatic migra-
tion, or via close association with a septic focus, for
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example, when connecting structures, such as cranial
nerves, allow transport of the organism or when there is
direct aspiration of purulent material into the lower respira-
tory tract.
Common sites of infection include the lung, mesentery,
liver, spleen, kidneys, and brain. Respiratory distress may
occur due to tracheal compression resulting from enlarge-
ment of the cranial mediastinal lymph nodes. Suppurative
bronchopneumonia is one important sequela of strangles. Of
15 horses with complications associated with strangles, 5
had pneumonia or pleuropneumonia, 3 of which resulted in
death.71 In an earlier study, 22/35 cases with complications
(62%) died of pneumonia secondary to strangles.72
The diagnosis and treatment of S. equi infections that
have spread are potentially more difficult than in cases of
uncomplicated strangles. The specific means of diagnosis
vary depending on the site of infection and whether there
are concurrent signs of classic strangles. For infections such
as bronchopneumonia, guttural pouch empyema or sinusitis,
appropriate samples can be collected for laboratory testing
as considered appropriate by the attending veterinarian.
However, for some internal abscesses, a specific diagnosis
may be difficult. A history of exposure to S. equi, intermit-
tent low-grade fevers responsive to penicillin, very
increased SeM specific antibody titers, and laboratory
results consistent with chronic infection, such as anemia,
hyperfibrinogenemia, neutrophilia, and hyperglobulinemia,
are supportive of the diagnosis of metastatic abscessation.
Mesenteric abscesses may be accompanied by an immune
ascites with increased SeM-specific antibody in ascetic
(peritoneal) fluid (J.F. Timoney, unpublished observations).
Treatment of S. equi infection that has spread frequently
involves long-term antimicrobial therapy, and appropriate
local treatment or drainage of abscesses if possible.78,79
The prevalence of metastatic abscessation is generally
low.27 However, in a study in which outbreaks of strangles
on 2 farms were investigated, 7/25 (28%) developed meta-
static abscessation.80 Of these, euthanasia was performed in
5 horses, 4 of which had neurologic signs and confirmed
cerebral abscesses. The reason for the high incidence of
complications, and particularly neurologic disease, on these
farms is unclear, but possible theories include a high infec-
tious dose, the virulence of the strains involved, and differ-
ences in host susceptibility. None of the horses were on
antibiotics before complications were identified. Again,
while antimicrobial therapy has been hypothesized to be a
risk factor for metastatic abscessation, data supporting this
theory are lacking,61 and it is clear that metastatic abscessa-
tion can occur without prior antimicrobial therapy.
Immune-Mediated Complications
Purpura Hemorrhagica
Purpura hemorrhagica is an aseptic necrotizing vasculitis
characterized primarily by edema and petechial or ecchy-
motic hemorrhage. While the exact pathogenesis of purpura
hemorrhagica is not fully understood, it appears to be a vas-
culitis caused by the deposition of immune complexes in
blood vessel walls. Although commonly associated with S.
equi infection, purpura may also occur in response to a num-
ber of non S. equi antigens. Of 53 horses with purpura, 17
were exposed to or infected with S. equi and 5 were vacci-
nated with S. equi M protein, while the remaining 31 cases
were either associated with other organisms or had no
known causes.81
The risk of developing purpura hemorrhagica after expo-
sure to S. equi through infection or vaccination is not
known. Four of 74 horses with strangles developed purpura
and all 4 were male yearlings that had been vaccinated
with an M protein vaccine and all developed signs of pur-
pura hemorrhagica within 2–6 days after the onset of stran-
gles.71 A preexisting high serum antibody titer to S. equi
antigens or exaggerated immunological response to S. equi
may predispose horses to the development of purpura
hemorrhagica.
Clinical Signs and Diagnosis of Purpura
Hemorrhagica
The severity of clinical signs seen with purpura varies
from a mild, transient reaction to a severe, fatal disease.81
The typical clinical signs seen as a result of the vasculitis
include subcutaneous edema, most frequently involving the
head; limbs, trunk, or both; and petechiation and ecchymo-
ses of the mucous membranes. Severe edema may result in
oozing from the skin surfaces and sloughing of the skin. In
some cases, the vasculitis may affect other sites such as the
gastrointestinal tract, lungs, and muscle, resulting in signs
such as colic, respiratory difficulties and muscle soreness.
Multiple small-intestine intussusceptions were reported as a
complication of purpura hemorrhagica in a horse.82 Intus-
susception is a well-known complication in children with
Henoch-Schoenlein purpura, a human autoimmune disease
that resembles purpura hemorrhagica in horses.
Leukocytoclastic vasculitis on histologic exam of skin
biopsy is consistent with a diagnosis of purpura hemorrhag-
ica. In those cases associated with S. equi, isolation of the
organism and demonstration of increased IgA and IgG titers
to SeM are also supportive.
Treatment and Prognosis of Purpura Hemorrhagica
Corticosteroids are the primary treatment for purpura.
Generally, dexamethasone at 0.1–0.2 mg/kg is used fol-
lowed by a tapering dose regime over 2–4 weeks, reducing
by 15% every 2 days.81 In those cases where purpura is
associated with active bacterial infection or the horse is con-
sidered at high risk of developing infection, appropriate
antibiotic therapy is also indicated. Non-steroidal anti-
inflammatory drugs may be of some benefit in some cases
of purpura. Supportive care, including intravenous fluids,
hydrotherapy, and bandaging may also be indicated. The
majority of the 53 horses with purpura were treated for
more than 7 days.81
Purpura hemorrhagica can be a serious often fatal compli-
cation of strangles. One of the 4 cases with purpura were
euthanized due to the severity of the skin necrosis.71 Simi-
larly, 3 of 22 horses with purpura secondary to exposure to
S. equi did not survive.81
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Myositis
Three types of myopathies have been documented in
horses after exposure to S. equi: muscle infarctions,83 rhab-
domyolysis with acute myonecrosis and presence of S.
equi,84 and rhabdomyolysis with progressive atrophy.85
Muscle Infarctions
This syndrome is most likely a severe manifestation of pur-
pura hemorrhagica. Many horses with purpura exhibit mild
elevations in serum creatine kinase (CK) activity due to
immune-mediated vasculitis within the muscle and mild mus-
cle necrosis, but these horses will have marked increases.
Titers of SeM-specific antibody may exceed 1:6,400. Some
horses develop a severe vasculopathy characterized by infarc-
tion of skeletal muscle, skin, gastrointestinal tract, and
lungs.83,86 Horses present with muscle stiffness, lameness, and
elevations in muscle enzymes in conjunction with other signs,
such as abdominal pain and subcutaneous swelling. On histo-
pathology, there is acute coagulative necrosis of muscle with
infarctions. Also, pulmonary hemorrhage and gastrointestinal
infarctions may be present. Even with aggressive corticoste-
roid therapy and antibiotics, the prognosis is guarded.
Rhabdomyolysis with Acute Myonecrosis
Acute severe rhabdomyolysis has been described in
horses with clinically evident strangles.84 Affected horses
develop a stiff gait and become recumbent. Swelling and
pitting edema may be present along the epaxial and gluteal
muscles. Clinicopathologic findings include mature neutro-
philia, hyperfibrinogenemia, and marked elevations in CK
and aspartate aminotransferase. Large multifocal, pale, fri-
able areas are present in affected muscle at necropsy. S.
equi are visible in sections of affected muscle. While the
mechanism is not known, it has been hypothesized that the
rhabdomyolysis is due to either an inflammatory cascade
similar to streptococcal toxic shock syndrome or potentially
direct toxic effects of S. equi in muscle tissue.
Rhabdomyolysis with Progressive Atrophy
Significant rhabdomyolysis with muscle atrophy has been
identified in 4 Quarter Horses after exposure to S. equi.86–88
Some of these horses had underlying polysaccharide storage
myopathy and developed rhabdomyolysis while ill. Others
developed myositis without an underlying problem and
exhibited malaise and a rapidly progressive atrophy of the
epaxial and gluteal muscles. Muscle enzymes were
increased and muscle biopsies revealed chronic active rhab-
domyolysis with regeneration, prominent macrophage infil-
tration, atrophy of fast-twitch fibers, and lymphocytic
vasculitis.86 Fibrosis developed around blood vessels. The
presence of concurrent signs of strangles was variable.
Horses affected with myositis should be treated with cor-
ticosteroids. In cases with atrophy, muscle mass may return
to normal. If there are signs consistent with concurrent
infection, antibiotics are also indicated.
Myocarditis
Streptococcal antigens have been suggested as a trigger
for development of myocarditis72,83 which may account for
electrocardiographic abnormalities reported in convalescent
horses in Sweden.89
Concluding Remarks Including Future
Directions
Our knowledge of S. equi including the mechanisms it
employs to cause disease is growing at an unprecedented
rate. The importance of identifying and treating persistently
infected horses is clear at both national and international
levels. However, there remains a relatively low level of
adoption of even basic biosecurity and testing measures to
prevent incursions of strangles or other infectious diseases.
The ability to differentiate strains of S. equi in source trac-
ing provides a basis for possible litigation and will serve as
an impetus to galvanize horse owners and veterinarians into
taking pre-emptive preventative action.
Vaccines that generate sterile immunity and serum anti-
body responses distinguishable from those induced by infec-
tion (DIVA) are urgently required. Unfortunately, little is
known about the protective immunogens involved and how
they must be presented in the horse to induce high level pro-
tective immunity. More research in this area is necessary in
order to improve the effectiveness of emerging vaccines.
Studies are also needed to explain shedding of virulent S.
equi from persistently infected guttural pouches, a location
in which the organism is experiencing genetic decay, mas-
sive reduction in numbers, and loss of virulence and fitness.
With proper biosecurity implementation, new capabilities
in serology, vigilant detection of subclinically infected car-
rier animals, and emerging vaccines with DIVA capabilities,
prevention against and efficient elimination of strangles
from a property is becoming ever more feasible.
Footnotes
a IDEXX Laboratories, Inc, Westbrook, ME
b Equine Diagnostic Systems LLC, Lexington, KY
c IDScreen Streptococcus equi Indirect, ID.vet Innovative Diagnostics,
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d Animal Health Trust, Newmarket, UK
e StrepvaxII, Boehringer Ingelheim, St. Joseph, MO
f Pinnacle I.N., Zoetis, Parsippany, NJ
g Equilis StrepE, Intervet International, the Netherlands
h Strangvac, Intervacc, Sweden
i Roccal-D, Zoetis, Parsippany, NJ
j Bio-tek Industries, Inc, Atlanta, GA
k Vetoquinol, Fort Worth, TX
l Intervention, Virox Animal Health, Oakville, ON
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